{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T16:27:38Z","timestamp":1764174458825,"version":"build-2065373602"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,1,24]],"date-time":"2018-01-24T00:00:00Z","timestamp":1516752000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,1,24]],"date-time":"2018-01-24T00:00:00Z","timestamp":1516752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Human Cytomegalovirus (HCMV) remains a major health burden and the development of a vaccine is a global priority. We developed new viral vectors delivering the T cell immunogens IE-1 and pp65 based on Adenovirus 19a\/64 (Ad19a\/64), a member of subgroup D. In this <jats:italic>ex vivo<\/jats:italic> study, the novel vectors were compared side by side to Ad5 or modified Vaccinia Ankara (MVA) strains expressing the same transgenes. We found that unlike Ad5, Ad19a\/64 vectors readily transduce a broad panel of immune cells, including monocytes, T cells, NK cells and monocyte-derived dendritic cells (moDCs). Both Ad19a\/64- and MVA-transduced moDCs efficiently restimulated IE-1 or pp65-specific T cells but MVA induced a higher amount of cytotoxicity in this cell type. Ad5 and Ad19 induced upregulation of CD86 and HLA-DR in moDCs whereas expression of CD80 and CD83 was largely unaltered. By contrast, MVA transduction led to downregulation of all markers. Taken together, our data demonstrate that Ad19a\/64 is a promising vector for the delivery of HCMV immunogens since it transduces dendritic cells with an efficiency that is comparable to MVA, but cytotoxicity and interference with dendritic cell maturation are less pronounced.<\/jats:p>","DOI":"10.1038\/s41598-018-19874-1","type":"journal-article","created":{"date-parts":[[2018,1,18]],"date-time":"2018-01-18T10:01:06Z","timestamp":1516269666000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Vaccine vectors based on Adenovirus 19a\/64 exhibit broad cellular tropism and potently restimulate HCMV-specific T cell responses ex vivo"],"prefix":"10.1038","volume":"8","author":[{"given":"Richard","family":"Kiener","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Fleischmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christiane","family":"Schwegler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zsolt","family":"Ruzsics","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Thirion","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silke","family":"Schr\u00f6del","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benedikt","family":"Asbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralf","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,1,24]]},"reference":[{"key":"19874_CR1","unstructured":"Knipe, D. M. & Howley, P. M. Fields Virology. (Lippincott Williams&Wilki, 2013)."},{"key":"19874_CR2","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.1099\/vir.0.000196","volume":"96","author":"E Hage","year":"2015","unstructured":"Hage, E., Gerd Liebert, U., Bergs, S., Ganzenmueller, T. & Heim, A. Human mastadenovirus type 70: a novel, multiple recombinant species D mastadenovirus isolated from diarrhoeal faeces of a haematopoietic stem cell transplantation recipient. J. Gen. Virol. 96, 2734\u20132742 (2015).","journal-title":"J. Gen. Virol."},{"key":"19874_CR3","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1002\/jmv.24749","volume":"89","author":"H Yoshitomi","year":"2017","unstructured":"Yoshitomi, H., Sera, N., Gonzalez, G., Hanaoka, N. & Fujimoto, T. First isolation of a new type of human adenovirus (genotype 79), species Human mastadenovirus B (B2) from sewage water in Japan. J. Med. Virol. 89, 1192\u20131200 (2017).","journal-title":"J. Med. Virol."},{"key":"19874_CR4","doi-asserted-by":"publisher","first-page":"421","DOI":"10.2174\/1566523213666131125095046","volume":"13","author":"WSM Wold","year":"2013","unstructured":"Wold, W. S. M. & Toth, K. Adenovirus vectors for gene therapy, vaccination and cancer gene therapy. Curr. Gene Ther. 13, 421\u2013433 (2013).","journal-title":"Curr. Gene Ther."},{"key":"19874_CR5","doi-asserted-by":"publisher","first-page":"4844","DOI":"10.1128\/JVI.02616-07","volume":"82","author":"J Liu","year":"2008","unstructured":"Liu, J. et al. Magnitude and phenotype of cellular immune responses elicited by recombinant adenovirus vectors and heterologous prime-boost regimens in rhesus monkeys. J. Virol. 82, 4844\u20134852 (2008).","journal-title":"J. Virol."},{"key":"19874_CR6","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1089\/104303401300057342","volume":"12","author":"M Hillgenberg","year":"2001","unstructured":"Hillgenberg, M., Schnieders, F., L\u00f6ser, P. & Strauss, M. System for efficient helper-dependent minimal adenovirus construction and rescue. Hum. Gene Ther. 12, 643\u2013657 (2001).","journal-title":"Hum. Gene Ther."},{"key":"19874_CR7","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1089\/10430340152712638","volume":"13","author":"B-G Harvey","year":"2002","unstructured":"Harvey, B.-G. et al. Safety of local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of morbid conditions. Hum. Gene Ther. 13, 15\u201363 (2002).","journal-title":"Hum. Gene Ther."},{"key":"19874_CR8","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/72628","volume":"18","author":"C Zheng","year":"2000","unstructured":"Zheng, C., Baum, B. J., Iadarola, M. J. & O\u2019Connell, B. C. Genomic integration and gene expression by a modified adenoviral vector. Nat. Biotechnol. 18, 176\u2013180 (2000).","journal-title":"Nat. Biotechnol."},{"key":"19874_CR9","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/S0958-1669(99)00007-5","volume":"10","author":"K Benihoud","year":"1999","unstructured":"Benihoud, K., Yeh, P. & Perricaudet, M. Adenovirus vectors for gene delivery. Curr. Opin. Biotechnol. 10, 440\u2013447 (1999).","journal-title":"Curr. Opin. Biotechnol."},{"key":"19874_CR10","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.vaccine.2009.10.145","volume":"28","author":"TC Mast","year":"2010","unstructured":"Mast, T. C. et al. International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials. Vaccine 28, 950\u2013957 (2010).","journal-title":"Vaccine"},{"key":"19874_CR11","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1126\/science.275.5304.1320","volume":"275","author":"JM Bergelson","year":"1997","unstructured":"Bergelson, J. M. et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 275, 1320\u20131323 (1997).","journal-title":"Science"},{"key":"19874_CR12","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.ymthe.2006.01.003","volume":"14","author":"M Lyons","year":"2006","unstructured":"Lyons, M. et al. Adenovirus type 5 interactions with human blood cells may compromise systemic delivery. Mol. Ther. J. Am. Soc. Gene Ther. 14, 118\u2013128 (2006).","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"19874_CR13","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1038\/sj.gt.3302295","volume":"11","author":"NK Green","year":"2004","unstructured":"Green, N. K. et al. Extended plasma circulation time and decreased toxicity of polymer-coated adenovirus. Gene Ther. 11, 1256\u20131263 (2004).","journal-title":"Gene Ther."},{"key":"19874_CR14","doi-asserted-by":"publisher","first-page":"241","DOI":"10.2174\/156652311796150363","volume":"11","author":"R Khare","year":"2011","unstructured":"Khare, R., Chen, C. Y., Weaver, E. A. & Barry, M. A. Advances and future challenges in adenoviral vector pharmacology and targeting. Curr. Gene Ther. 11, 241\u2013258 (2011).","journal-title":"Curr. Gene Ther."},{"key":"19874_CR15","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/mt.2015.194","volume":"24","author":"J Alonso-Padilla","year":"2016","unstructured":"Alonso-Padilla, J. et al. Development of Novel Adenoviral Vectors to Overcome Challenges Observed With HAdV-5-based Constructs. Mol. Ther. J. Am. Soc. Gene Ther. 24, 6\u201316 (2016).","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"19874_CR16","doi-asserted-by":"publisher","first-page":"5203","DOI":"10.1016\/j.vaccine.2011.05.025","volume":"29","author":"DH Barouch","year":"2011","unstructured":"Barouch, D. H. et al. International Seroepidemiology of Adenovirus Serotypes 5, 26, 35, and 48 in Pediatric and Adult Populations. Vaccine 29, 5203\u20135209 (2011).","journal-title":"Vaccine"},{"key":"19874_CR17","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1001\/jama.2016.4218","volume":"315","author":"ID Milligan","year":"2016","unstructured":"Milligan, I. D. et al. Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial. JAMA 315, 1610\u20131623 (2016).","journal-title":"JAMA"},{"key":"19874_CR18","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1002\/hep.28294","volume":"63","author":"C Kelly","year":"2016","unstructured":"Kelly, C. et al. Chronic hepatitis C viral infection subverts vaccine\u2010induced T\u2010cell immunity in humans. Hepatol. Baltim. Md 63, 1455\u20131470 (2016).","journal-title":"Hepatol. Baltim. Md"},{"key":"19874_CR19","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1093\/infdis\/jiw500","volume":"215","author":"J Nyombayire","year":"2017","unstructured":"Nyombayire, J. et al. First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus\u2013Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens. J. Infect. Dis. 215, 95\u2013104 (2017).","journal-title":"J. Infect. Dis."},{"key":"19874_CR20","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1128\/JVI.02058-12","volume":"87","author":"P Penaloza-MacMaster","year":"2013","unstructured":"Penaloza-MacMaster, P. et al. Alternative serotype adenovirus vaccine vectors elicit memory T cells with enhanced anamnestic capacity compared to Ad5 vectors. J. Virol. 87, 1373\u20131384 (2013).","journal-title":"J. Virol."},{"key":"19874_CR21","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1128\/CVI.00723-13","volume":"21","author":"I N\u00e9bi\u00e9","year":"2014","unstructured":"N\u00e9bi\u00e9, I. et al. Assessment of Chimpanzee Adenovirus Serotype 63 Neutralizing Antibodies Prior to Evaluation of a Candidate Malaria Vaccine Regimen Based on Viral Vectors. Clin. Vaccine Immunol. CVI 21, 901\u2013903 (2014).","journal-title":"Clin. Vaccine Immunol. CVI"},{"key":"19874_CR22","doi-asserted-by":"publisher","first-page":"e101591","DOI":"10.1371\/journal.pone.0101591","volume":"9","author":"E-J Hayton","year":"2014","unstructured":"Hayton, E.-J. et al. Safety and tolerability of conserved region vaccines vectored by plasmid DNA, simian adenovirus and modified vaccinia virus ankara administered to human immunodeficiency virus type 1-uninfected adults in a randomized, single-blind phase I trial. PloS One 9, e101591 (2014).","journal-title":"PloS One"},{"key":"19874_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.virol.2010.07.043","volume":"407","author":"J Ersching","year":"2010","unstructured":"Ersching, J. et al. Neutralizing antibodies to human and simian adenoviruses in humans and New-World monkeys. Virology 407, 1\u20136 (2010).","journal-title":"Virology"},{"key":"19874_CR24","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1056\/NEJMoa1410863","volume":"376","author":"JE Ledgerwood","year":"2017","unstructured":"Ledgerwood, J. E. et al. Chimpanzee Adenovirus Vector Ebola Vaccine. N. Engl. J. Med. 376, 928\u2013938 (2017).","journal-title":"N. Engl. J. Med."},{"key":"19874_CR25","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1089\/hum.1996.7.1-79","volume":"7","author":"A Mastrangeli","year":"1996","unstructured":"Mastrangeli, A. et al. \u2018Sero-switch\u2019 adenovirus-mediated in vivo gene transfer: circumvention of anti-adenovirus humoral immune defenses against repeat adenovirus vector administration by changing the adenovirus serotype. Hum. Gene Ther. 7, 79\u201387 (1996).","journal-title":"Hum. Gene Ther."},{"key":"19874_CR26","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1002\/emmm.201403876","volume":"6","author":"I Delany","year":"2014","unstructured":"Delany, I., Rappuoli, R. & De Gregorio, E. Vaccines for the 21st century. EMBO Mol. Med. 6, 708\u2013720 (2014).","journal-title":"EMBO Mol. Med."},{"key":"19874_CR27","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1167\/iovs.12-9656","volume":"53","author":"X Zhou","year":"2012","unstructured":"Zhou, X. et al. Analysis of human adenovirus type 19 associated with epidemic keratoconjunctivitis and its reclassification as adenovirus type 64. Invest. Ophthalmol. Vis. Sci. 53, 2804\u20132811 (2012).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"19874_CR28","doi-asserted-by":"publisher","first-page":"8263","DOI":"10.1128\/JVI.77.15.8263-8271.2003","volume":"77","author":"R Vogels","year":"2003","unstructured":"Vogels, R. et al. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J. Virol. 77, 8263\u20138271 (2003).","journal-title":"J. Virol."},{"key":"19874_CR29","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/00004397-200201000-00008","volume":"42","author":"K Aoki","year":"2002","unstructured":"Aoki, K. & Tagawa, Y. A twenty-one year surveillance of adenoviral conjunctivitis in Sapporo, Japan. Int. Ophthalmol. Clin. 42, 49\u201354 (2002).","journal-title":"Int. Ophthalmol. Clin."},{"key":"19874_CR30","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/00004397-197501540-00016","volume":"15","author":"PR Laibson","year":"1975","unstructured":"Laibson, P. R. Adenoviral keratoconjunctivitis. Int. Ophthalmol. Clin. 15, 187\u2013201 (1975).","journal-title":"Int. Ophthalmol. Clin."},{"key":"19874_CR31","doi-asserted-by":"publisher","first-page":"8100","DOI":"10.1128\/JVI.00687-06","volume":"80","author":"Z Ruzsics","year":"2006","unstructured":"Ruzsics, Z. et al. Transposon-assisted cloning and traceless mutagenesis of adenoviruses: Development of a novel vector based on species D. J. Virol. 80, 8100\u20138113 (2006).","journal-title":"J. Virol."},{"key":"19874_CR32","doi-asserted-by":"publisher","first-page":"7691","DOI":"10.1128\/JVI.74.16.7691-7693.2000","volume":"74","author":"N Arnberg","year":"2000","unstructured":"Arnberg, N., Kidd, A. H., Edlund, K., Olfat, F. & Wadell, G. Initial interactions of subgenus D adenoviruses with A549 cellular receptors: sialic acid versus alpha(v) integrins. J. Virol. 74, 7691\u20137693 (2000).","journal-title":"J. Virol."},{"key":"19874_CR33","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1089\/hum.2006.17.193","volume":"17","author":"C Thirion","year":"2006","unstructured":"Thirion, C. et al. Adenovirus vectors based on human adenovirus type 19a have high potential for human muscle-directed gene therapy. Hum. Gene Ther. 17, 193\u2013205 (2006).","journal-title":"Hum. Gene Ther."},{"key":"19874_CR34","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1128\/CMR.00062-12","volume":"26","author":"S Manicklal","year":"2013","unstructured":"Manicklal, S., Emery, V. C., Lazzarotto, T., Boppana, S. B. & Gupta, R. K. The \u2018Silent\u2019 Global Burden of Congenital Cytomegalovirus. Clin. Microbiol. Rev. 26, 86\u2013102 (2013).","journal-title":"Clin. Microbiol. Rev."},{"key":"19874_CR35","doi-asserted-by":"publisher","first-page":"3916","DOI":"10.1182\/blood.V99.11.3916","volume":"99","author":"H Einsele","year":"2002","unstructured":"Einsele, H. et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 99, 3916\u20133922 (2002).","journal-title":"Blood"},{"key":"19874_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-5-17","volume":"5","author":"SL Slezak","year":"2007","unstructured":"Slezak, S. L. et al. CMV pp65 and IE-1 T cell epitopes recognized by healthy subjects. J. Transl. Med. 5, 17 (2007).","journal-title":"J. Transl. Med."},{"key":"19874_CR37","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1084\/jem.20050882","volume":"202","author":"AW Sylwester","year":"2005","unstructured":"Sylwester, A. W. et al. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J. Exp. Med. 202, 673\u2013685 (2005).","journal-title":"J. Exp. Med."},{"key":"19874_CR38","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S2055-6640(20)30872-4","volume":"2","author":"MR Schleiss","year":"2016","unstructured":"Schleiss, M. R. Cytomegalovirus vaccines under clinical development. J. Virus Erad. 2, 198\u2013207 (2016).","journal-title":"J. Virus Erad."},{"key":"19874_CR39","first-page":"176","volume":"18","author":"VI Rebel","year":"2000","unstructured":"Rebel, V. I. et al. Maturation and lineage-specific expression of the coxsackie and adenovirus receptor in hematopoietic cells. Stem Cells Dayt. Ohio 18, 176\u2013182 (2000).","journal-title":"Ohio"},{"key":"19874_CR40","first-page":"87","volume":"273","author":"L Philipson","year":"2004","unstructured":"Philipson, L. & Pettersson, R. F. The coxsackie-adenovirus receptor\u2013a new receptor in the immunoglobulin family involved in cell adhesion. Curr. Top. Microbiol. Immunol. 273, 87\u2013111 (2004).","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"19874_CR41","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1128\/jvi.62.1.341-345.1988","volume":"62","author":"J Horvath","year":"1988","unstructured":"Horvath, J. & Weber, J. M. Nonpermissivity of human peripheral blood lymphocytes to adenovirus type 2 infection. J. Virol. 62, 341\u2013345 (1988).","journal-title":"J. Virol."},{"key":"19874_CR42","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.2144\/97236st07","volume":"23","author":"S Chakrabarti","year":"1997","unstructured":"Chakrabarti, S., Sisler, J. R. & Moss, B. Compact, synthetic, vaccinia virus early\/late promoter for protein expression. BioTechniques 23, 1094\u20131097 (1997).","journal-title":"BioTechniques"},{"key":"19874_CR43","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/nri.2016.38","volume":"16","author":"P Klenerman","year":"2016","unstructured":"Klenerman, P. & Oxenius, A. T cell responses to cytomegalovirus. Nat. Rev. Immunol. 16, 367\u2013377 (2016).","journal-title":"Nat. Rev. Immunol."},{"key":"19874_CR44","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1002\/jcb.22328","volume":"108","author":"AK Zaiss","year":"2009","unstructured":"Zaiss, A. K., Machado, H. B. & Herschman, H. R. The influence of innate and pre-existing immunity on adenovirus therapy. J. Cell. Biochem. 108, 778\u2013790 (2009).","journal-title":"J. Cell. Biochem."},{"key":"19874_CR45","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1016\/S0140-6736(08)61591-3","volume":"372","author":"SP Buchbinder","year":"2008","unstructured":"Buchbinder, S. P. et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372, 1881\u20131893 (2008).","journal-title":"Lancet"},{"key":"19874_CR46","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1099\/vir.0.008342-0","volume":"90","author":"WC Adams","year":"2009","unstructured":"Adams, W. C. et al. Adenovirus serotype 5 infects human dendritic cells via a coxsackievirus-adenovirus receptor-independent receptor pathway mediated by lactoferrin and DC-SIGN. J. Gen. Virol. 90, 1600\u20131610 (2009).","journal-title":"J. Gen. Virol."},{"key":"19874_CR47","first-page":"6762","volume":"163","author":"J Engelmayer","year":"1999","unstructured":"Engelmayer, J. et al. Vaccinia virus inhibits the maturation of human dendritic cells: a novel mechanism of immune evasion. J. Immunol. Baltim. Md 1950 163, 6762\u20136768 (1999).","journal-title":"J. Immunol. Baltim. Md 1950"},{"key":"19874_CR48","doi-asserted-by":"publisher","first-page":"5532","DOI":"10.1128\/JVI.02267-10","volume":"85","author":"MF Pascutti","year":"2011","unstructured":"Pascutti, M. F. et al. Interplay between modified vaccinia virus Ankara and dendritic cells: phenotypic and functional maturation of bystander dendritic cells. J. Virol. 85, 5532\u20135545 (2011).","journal-title":"J. Virol."},{"key":"19874_CR49","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/sj.gt.3301887","volume":"10","author":"A Br\u00fcning","year":"2003","unstructured":"Br\u00fcning, A. & Runnebaum, I. B. CAR is a cell-cell adhesion protein in human cancer cells and is expressionally modulated by dexamethasone, TNFalpha, and TGFbeta. Gene Ther. 10, 198\u2013205 (2003).","journal-title":"Gene Ther."},{"key":"19874_CR50","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1158\/1078-0432.CCR-16-2057","volume":"23","author":"KA Batich","year":"2017","unstructured":"Batich, K. A. et al. Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 23, 1898\u20131909 (2017).","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"19874_CR51","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1056\/NEJMc0804818","volume":"359","author":"RM Prins","year":"2008","unstructured":"Prins, R. M., Cloughesy, T. F. & Liau, L. M. Cytomegalovirus immunity after vaccination with autologous glioblastoma lysate. N. Engl. J. Med. 359, 539\u2013541 (2008).","journal-title":"N. Engl. J. Med."},{"key":"19874_CR52","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1215\/15228517-2007-035","volume":"10","author":"DA Mitchell","year":"2008","unstructured":"Mitchell, D. A. et al. Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. Neuro-Oncol. 10, 10\u201318 (2008).","journal-title":"Neuro-Oncol."},{"key":"19874_CR53","doi-asserted-by":"publisher","first-page":"192ra87","DOI":"10.1126\/scitranslmed.3005958","volume":"5","author":"M Nauerth","year":"2013","unstructured":"Nauerth, M. et al. TCR-ligand koff rate correlates with the protective capacity of antigen-specific CD8+ T cells for adoptive transfer. Sci. Transl. Med. 5, 192ra87 (2013).","journal-title":"Sci. Transl. Med."},{"key":"19874_CR54","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1128\/iai.27.2.292-296.1980","volume":"27","author":"G Wadell","year":"1980","unstructured":"Wadell, G. & de Jong, J. C. Restriction endonucleases in identification of a genome type of adenovirus 19 associated with keratoconjunctivitis. Infect. Immun. 27, 292\u2013296 (1980).","journal-title":"Infect. Immun."},{"key":"19874_CR55","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1128\/JVI.02469-14","volume":"89","author":"B Perdiguero","year":"2015","unstructured":"Perdiguero, B. et al. Virological and immunological characterization of novel NYVAC-based HIV\/AIDS vaccine candidates expressing clade C trimeric solublegp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as virus-like particles. J. Virol. 89, 970\u2013988 (2015).","journal-title":"J. Virol."},{"key":"19874_CR56","first-page":"143","volume":"1089","author":"Z Ruzsics","year":"2014","unstructured":"Ruzsics, Z., Lemnitzer, F. & Thirion, C. Engineering adenovirus genome by bacterial artificial chromosome (BAC) technology. Methods Mol. Biol. Clifton NJ 1089, 143\u2013158 (2014).","journal-title":"Biol. Clifton NJ"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-19874-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-19874-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-19874-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T01:26:31Z","timestamp":1671585991000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-19874-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,24]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["19874"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-19874-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2018,1,24]]},"assertion":[{"value":"31 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Christian Thirion is founder and shareholder of SIRION Biotech GmbH.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"1474"}}